6MP for fathers with IBD at the time of conception: The value of a large clinical experience over unrelated controls [2] (multiple letters)

American Journal of Gastroenterology

Volumn 95, Issue 9, 2000, Pages 2386-2387

  Korelitz, Burton I ^a,b   Rajapakse, Ramona O ^a   Zlatanic, Jusuf ^a   Baiocco, Peter J ^a   Gleim, Gilbert W ^a   Kane, Sunanda V ^c  

^a LENOX HILL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

ABORTION; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG SAFETY; HUMAN; IRRITABLE COLON; LETTER; METHODOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SPERMATOGENESIS; TERATOGENICITY;

EID: 0033826105     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)01133-3     Document Type: Letter

References (5)

1. S.V. Kane What’s good for the goose should be good for the gander—6MP use in fathers with inflammatory bowel disease Am J Gastroenterol 95 2000 581 582
2. M. Golby Fertility after renal transplantation Transplantation 10 1970 201 207
3. I. Penn E. Makowski W. Droegemueller Parenthood in renal homograft recipients JAMA 216 1971 1755 1757
4. R.O. Rajapakse B.I. Korelitz J. Zlatanic Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease Am J Gastroenterol 95 2000 684 688
5. A. Francella A. Dayan P. Rubin 6-Mercaptopurine is a safe therapy for child bearing patients with inflammatory bowel disease A case controlled study Gastroenterology 110 1996 909